Christopher R. Blagg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christopher R. Blagg has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Belding H Scribner
University of Washington and the Northwest Kidney Centers, Seattle, Washington, U.S.A.
2 shared publications- Carl M. Kjellstrand
Aksys Ltd., Lincolnshire, Illinois, USA
2 shared publications George O. Ting
El Camino Dialysis Services, El Camino Hospital and Stanford University, Mountain View and Stanford, California, U.S.A.
2 shared publications- Amy W. Williams
Mayo Clinic, Rochester, MN 55905, USA
1 shared publication Barbara G. Delano
1 shared publicationBessie A. Young
University of Washington and Northwest Kidney Centers, Seattle, Washington, U.S.A.
1 shared publication
Latest Publications
- 22 November 2011
- Published by Wiley in Seminars in Dialysis
- Vol. 24 (6) , 674-677
Dialysis Composite Rate Bundling: Potential Effects on the Utilization of Home Hemodialysis, Daily and Nocturnal Hemodialysis, and Peritoneal Dialysis
Home hemodialysis was introduced because it was less expensive than center dialysis, so allowing more patients to be treated with the limited funds available in the 1960s. The start of the Medicare ESRD Program in July 1973, with almost universal entitlement, removed the financial barriers, and had many other effects including reducing the use of home dialysis. Bundled payment for dialysis, including necessary dialysis supplies and laboratory tests, was introduced as the “composite” rate in 1983. Over the ensuing years, the costs of providing dialysis treatment increased, and expensive new drugs were introduced, particularly erythropoietin. As a result, the government introduced a more extensive bundle at the beginning of this year, aimed at better control of costs. This article considers the potential effect of this reimbursement change on home dialysis.
- 22 November 2011
- Published by Wiley in Seminars in Dialysis
- Vol. 24 (6) , 674-677
Dialysis Composite Rate Bundling: Potential Effects on the Utilization of Home Hemodialysis, Daily and Nocturnal Hemodialysis, and Peritoneal Dialysis
Home hemodialysis was introduced because it was less expensive than center dialysis, so allowing more patients to be treated with the limited funds available in the 1960s. The start of the Medicare ESRD Program in July 1973, with almost universal entitlement, removed the financial barriers, and had many other effects including reducing the use of home dialysis. Bundled payment for dialysis, including necessary dialysis supplies and laboratory tests, was introduced as the “composite” rate in 1983. Over the ensuing years, the costs of providing dialysis treatment increased, and expensive new drugs were introduced, particularly erythropoietin. As a result, the government introduced a more extensive bundle at the beginning of this year, aimed at better control of costs. This article considers the potential effect of this reimbursement change on home dialysis.
- Open Access
- 1 December 2010
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (12) , 2146-2149
Belding Hibbard Scribner—Better Known as Scrib
- 1 December 2010
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (12) , 2146-2149
Open AccessBelding Hibbard Scribner—Better Known as Scrib
- 1 October 2009
- Published by Elsevier in Kidney International
- Vol. 76 (8) , 917
First use of nocturnal hemodialysis
- 1 October 2009
- Published by Elsevier in Kidney International
- Vol. 76 (8) , 917
First use of nocturnal hemodialysis
- 1 January 2009
- Vol. 22 Suppl 1, 115-9
Thomas Addis, 1881-1949, clinical scientist, hematologist and pioneering nephrologist: a brief biography.
Thomas Addis is an important figure in the history of nephrology. Born in Scotland and trained in Edinburgh, he came to San Francisco in 1911 to the new Stanford School of Medicine to run the clinical laboratory. Over the next 38 years, he made many contributions to renal physiology, the investigation of the structure and function of the kidneys in Bright's disease, and studies of kidney growth, hypertrophy and protein metabolism. Largely forgotten today, he was one of the first to use urea clearance as a measure of kidney function and was the first to systematize examination of the urinary sediment - the Addis count. He was also a leader in the use of diet and rest in the treatment of Bright's disease. Unknown to most nephrologists, before he came to the United States during the first 6 years following his graduation, he became one of the leading clinical investigators in hematology. His special interests were the mechanism of blood clotting and hemophilia. He was the first to transfuse fresh blood into a hemophiliac patient and show that this shortened the patient's clotting time. Addis was a great, if eccentric, personality as well as a great scientist. He was beloved by his many colleagues and students and was honored in his lifetime both in the United States and Great Britain.
- 1 January 2009
- Vol. 22 Suppl 1, 115-9
Thomas Addis, 1881-1949, clinical scientist, hematologist and pioneering nephrologist: a brief biography.
Thomas Addis is an important figure in the history of nephrology. Born in Scotland and trained in Edinburgh, he came to San Francisco in 1911 to the new Stanford School of Medicine to run the clinical laboratory. Over the next 38 years, he made many contributions to renal physiology, the investigation of the structure and function of the kidneys in Bright's disease, and studies of kidney growth, hypertrophy and protein metabolism. Largely forgotten today, he was one of the first to use urea clearance as a measure of kidney function and was the first to systematize examination of the urinary sediment - the Addis count. He was also a leader in the use of diet and rest in the treatment of Bright's disease. Unknown to most nephrologists, before he came to the United States during the first 6 years following his graduation, he became one of the leading clinical investigators in hematology. His special interests were the mechanism of blood clotting and hemophilia. He was the first to transfuse fresh blood into a hemophiliac patient and show that this shortened the patient's clotting time. Addis was a great, if eccentric, personality as well as a great scientist. He was beloved by his many colleagues and students and was honored in his lifetime both in the United States and Great Britain.
- 1 July 2008
- Published by Wiley in Hemodialysis International
- Vol. 12 (s1) , S2-S5
The renaissance of home hemodialysis: Where we are, why we got here, what is happening in the United States and elsewhere
Home hemodialysis has been around since 1964, but its use has declined over the years in most countries, this despite its advantages, particularly improved patient survival and quality of life and significant cost savings. Experience has shown that home hemodialysis can be performed successfully by many more patients than at present. Recently, with the demonstration of even better results with more frequent hemodialysis that is obviously best performed at home and with the development of new, more patient-friendly machines, the use of home hemodialysis is beginning to increase again.
- 1 July 2008
- Published by Wiley in Hemodialysis International
- Vol. 12 (s1) , S2-S5
The renaissance of home hemodialysis: Where we are, why we got here, what is happening in the United States and elsewhere
Home hemodialysis has been around since 1964, but its use has declined over the years in most countries, this despite its advantages, particularly improved patient survival and quality of life and significant cost savings. Experience has shown that home hemodialysis can be performed successfully by many more patients than at present. Recently, with the demonstration of even better results with more frequent hemodialysis that is obviously best performed at home and with the development of new, more patient-friendly machines, the use of home hemodialysis is beginning to increase again.
- 1 March 2008
- Published by Elsevier in Kidney International
- Vol. 73 (6) , 665-666
In Memory of Joseph Wetherill Eschbach
- 1 March 2008
- Published by Elsevier in Kidney International
- Vol. 73 (6) , 665-666
In Memory of Joseph Wetherill Eschbach
Author’s reply
Footnotes Competing interests: None declared.
Home haemodialysis
Footnotes Competing interests: None declared. Provenance and peer review: Commissioned; externally peer reviewed.
Home haemodialysis
Footnotes Competing interests: None declared. Provenance and peer review: Commissioned; externally peer reviewed.
- 1 March 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 49 (3) , 482-496
The Early History of Dialysis for Chronic Renal Failure in the United States: A View From Seattle
- 1 March 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 49 (3) , 482-496
The Early History of Dialysis for Chronic Renal Failure in the United States: A View From Seattle
- 3 October 2006
- Published by Wiley in Hemodialysis International
- Vol. 10 (4) , 371-374
Comparison of survival between short‐daily hemodialysis and conventional hemodialysis using the standardized mortality ratio
More frequent hemodialysis (5 or more times weekly, both short during the day and long overnight) has been shown to improve patient well‐being, reduce symptoms during and between treatments, and have beneficial effects on clinical outcomes. Because of the relatively small patient sample sizes, there are little or no data on mortality from any single study at this time. This study compares survival in 117 U.S. patients treated by short‐daily hemodialysis in 2003 and 2004, with patients reported in the 2003 data from the United States Renal Data System (USRDS). Expected mortality was calculated from the USRDS and compared with observed actual mortality. The standardized mortality ratio (SMR) was used to adjust for differences in patient age, sex, race, and cause of renal failure. The SMR for the short‐daily hemodialysis patients was 0.39, statistically significantly better (p<0.005) than data from the overall U.S. population of hemodialysis patients and indicating that daily hemodialysis patients had a 61% better survival. Patients treated by short‐daily hemodialysis have a better survival rate than comparable populations treated by conventional hemodialysis.
- 3 October 2006
- Published by Wiley in Hemodialysis International
- Vol. 10 (4) , 371-374
Comparison of survival between short‐daily hemodialysis and conventional hemodialysis using the standardized mortality ratio
More frequent hemodialysis (5 or more times weekly, both short during the day and long overnight) has been shown to improve patient well‐being, reduce symptoms during and between treatments, and have beneficial effects on clinical outcomes. Because of the relatively small patient sample sizes, there are little or no data on mortality from any single study at this time. This study compares survival in 117 U.S. patients treated by short‐daily hemodialysis in 2003 and 2004, with patients reported in the 2003 data from the United States Renal Data System (USRDS). Expected mortality was calculated from the USRDS and compared with observed actual mortality. The standardized mortality ratio (SMR) was used to adjust for differences in patient age, sex, race, and cause of renal failure. The SMR for the short‐daily hemodialysis patients was 0.39, statistically significantly better (p<0.005) than data from the overall U.S. population of hemodialysis patients and indicating that daily hemodialysis patients had a 61% better survival. Patients treated by short‐daily hemodialysis have a better survival rate than comparable populations treated by conventional hemodialysis.